- Home
- IOVA vs NKTR Comparison
IOVA vs NKTR Comparison
Compare IOVA & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- NKTR
- Stock Information
- Founded
- IOVA 2007
- NKTR 1990
- Country
- IOVA United States
- NKTR United States
- Employees
- IOVA N/A
- NKTR N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- IOVA Health Care
- NKTR Health Care
- Exchange
- IOVA Nasdaq
- NKTR Nasdaq
- Market Cap
- IOVA 975.1M
- NKTR 1.2B
- IPO Year
- IOVA N/A
- NKTR 1994
- Fundamental
- Price
- IOVA $1.83
- NKTR $55.88
- Analyst Decision
- IOVA Buy
- NKTR Strong Buy
- Analyst Count
- IOVA 11
- NKTR 6
- Target Price
- IOVA $10.80
- NKTR $91.67
- AVG Volume (30 Days)
- IOVA 14.8M
- NKTR 884.5K
- Earning Date
- IOVA 11-06-2025
- NKTR 11-06-2025
- Dividend Yield
- IOVA N/A
- NKTR N/A
- EPS Growth
- IOVA N/A
- NKTR N/A
- EPS
- IOVA N/A
- NKTR N/A
- Revenue
- IOVA $241,525,000.00
- NKTR $74,934,000.00
- Revenue This Year
- IOVA $68.14
- NKTR N/A
- Revenue Next Year
- IOVA $56.64
- NKTR N/A
- P/E Ratio
- IOVA N/A
- NKTR N/A
- Revenue Growth
- IOVA 636.99
- NKTR N/A
- 52 Week Low
- IOVA $1.64
- NKTR $6.48
- 52 Week High
- IOVA $12.51
- NKTR $66.92
- Technical
- Relative Strength Index (RSI)
- IOVA 34.71
- NKTR 46.89
- Support Level
- IOVA $1.94
- NKTR $59.01
- Resistance Level
- IOVA $2.20
- NKTR $66.92
- Average True Range (ATR)
- IOVA 0.14
- NKTR 4.79
- MACD
- IOVA -0.04
- NKTR -0.80
- Stochastic Oscillator
- IOVA 3.31
- NKTR 17.13
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.